View Entire Collection
By Clinical Topic
By State Requirement
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
THURSDAY, Sept. 22 (HealthDay News) -- The U.S. Food and Drug Administration has expanded the age indications for Boostrix, the tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap), to include people 65 and older, according to an article published in the Sept. 23 issue of the U.S. Centers for Disease Control and Prevention's Morbidity and Mortality Weekly Report.
Boostrix was originally licensed for use in people 10 to 18 years of age, an indication that was expanded by the FDA in 2008 to include people up to age 64. In October of 2010, however, the Advisory Committee on Immunization Practices (ACIP) received data on the safety and immunogenicity of Boostrix in those 65 and older; they went on to review data from two clinical trials analyzing the safety and immunogenicity of the vaccine in this age cohort.
The committee determined that Boostrix's safety and immunogenicity profiles were similar to those of currently available tetanus and diphtheria toxoids vaccine.
"With the recent FDA expanded licensure for use of Boostrix, ACIP will be reviewing the current recommendations on use of Tdap in persons aged 65 years and older. At this time, either Tdap product [Boostrix or Adacel] may be used in persons aged 65 years and older," the researchers write.
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top